Gulf Pharmaceutical Industries P.S.C Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Gulf Pharmaceutical Industries P.S.C wird voraussichtlich ein Umsatzwachstum verzeichnen at 5.9% per annum.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.2%
Wachstumsrate der Einnahmen	5.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Mar 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Jan 15

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Nov 04

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Mar 26

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Feb 08

Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

Dec 14

Gewinn- und Umsatzwachstumsprognosen

ADX:JULPHAR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AED Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	1,798	N/A	N/A	N/A	1
12/31/2024	1,694	N/A	76	8	1
6/30/2024	1,662	-58	156	208	N/A
3/31/2024	1,623	-98	117	166	N/A
12/31/2023	1,638	-104	65	92	N/A
9/30/2023	1,587	-128	-8	43	N/A
6/30/2023	1,637	-85	-54	-2	N/A
3/31/2023	1,652	-38	-42	16	N/A
12/31/2022	1,616	-34	-46	19	N/A
9/30/2022	1,651	-28	-68	-7	N/A
6/30/2022	1,598	0	13	75	N/A
3/31/2022	1,398	64	10	59	N/A
12/31/2021	1,143	47	2	46	N/A
9/30/2021	858	-104	-42	-21	N/A
6/30/2021	682	-138	-117	-101	N/A
3/31/2021	632	-203	-145	-125	N/A
12/31/2020	573	-247	-184	-168	N/A
9/30/2020	540	-184	-238	-229	N/A
6/30/2020	376	-377	-240	-224	N/A
3/31/2020	295	-472	-179	-159	N/A
12/31/2019	302	-494	-119	-85	N/A
9/30/2019	265	-957	10	62	N/A
6/30/2019	388	-840	31	84	N/A
3/31/2019	567	-716	87	145	N/A
12/31/2018	720	-612	127	179	N/A
9/30/2018	928	-20	72	136	N/A
6/30/2018	1,106	80	136	200	N/A
3/31/2018	1,085	70	N/A	113	N/A
12/31/2017	1,155	95	N/A	81	N/A
9/30/2017	1,293	142	N/A	234	N/A
6/30/2017	1,275	145	N/A	234	N/A
3/31/2017	1,418	178	N/A	264	N/A
12/31/2016	1,455	212	N/A	268	N/A
9/30/2016	1,391	205	N/A	261	N/A
6/30/2016	1,407	215	N/A	242	N/A
3/31/2016	1,391	214	N/A	235	N/A
12/31/2015	1,470	230	N/A	183	N/A
9/30/2015	1,510	226	N/A	117	N/A
6/30/2015	1,449	235	N/A	161	N/A
3/31/2015	1,443	228	N/A	96	N/A
12/31/2014	1,388	204	N/A	40	N/A
9/30/2014	1,382	224	N/A	131	N/A
6/30/2014	1,427	231	N/A	-22	N/A
3/31/2014	1,425	238	N/A	79	N/A
12/31/2013	1,362	230	N/A	108	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von JULPHAR über der Sparquote liegt (14.3%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von JULPHAR schneller wachsen werden als der Markt AE

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von JULPHAR in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: JULPHARDie Einnahmen des Unternehmens (5.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt AE (6.6% pro Jahr).

Hohe Wachstumseinnahmen: JULPHARDie Einnahmen des Unternehmens (5.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von JULPHAR in 3 Jahren voraussichtlich hoch sein wird

Gulf Pharmaceutical Industries P.S.C Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to د.إ1.57

Recent updates

Second quarter 2024 earnings released

Gulf Pharmaceutical Industries P.S.C. to Report Q2, 2024 Results on Aug 14, 2024

Now 21% overvalued

First quarter 2024 earnings released: EPS: د.إ0.002 (vs د.إ0.003 loss in 1Q 2023)

Gulf Pharmaceutical Industries P.S.C., Annual General Meeting, Apr 22, 2024

Full year 2023 earnings released: د.إ0.09 loss per share (vs د.إ0.029 loss in FY 2022)

Full year 2023 earnings released: د.إ0.087 loss per share (vs د.إ0.029 loss in FY 2022)

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Third quarter 2023 earnings released: د.إ0.034 loss per share (vs د.إ0.003 profit in 3Q 2022)

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Second quarter 2023 earnings released: د.إ0.037 loss per share (vs د.إ0.003 profit in 2Q 2022)

First quarter 2023 earnings released

Full year 2022 earnings: EPS and revenues miss analyst expectations

Gulf Pharmaceutical Industries P.S.C. Announces Chief Executive Officer Changes

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: د.إ0.003 (vs د.إ0.028 in 3Q 2021)

Gulf Pharmaceutical Industries P.S.C. to Report Q3, 2022 Results on Nov 09, 2022

Gulf Pharmaceutical Industries P.S.C. Announces Resignation of Sanjay Deshmukh as Chief Operating Officer

Second quarter 2022 earnings released: EPS: د.إ0.003 (vs د.إ0.059 in 2Q 2021)

First quarter 2022 earnings: Revenues miss analyst expectations

Gulf Pharmaceutical Industries P.S.C. to Report Q1, 2022 Results on May 13, 2022

Price target decreased to د.إ1.57

Less than half of directors are independent

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Third quarter 2021 earnings released: EPS د.إ0.028 (vs د.إ0.003 loss in 3Q 2020)

GlobalOne Healthcare acquired Gulf Inject LLC from Gulf Pharmaceutical Industries P.S.C.

Second quarter 2021 earnings released: EPS د.إ0.059 (vs د.إ0.028 loss in 2Q 2020)

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) completed the acquisition of remaining 60% stake in Planet Pharmacies LLC from KAMCO Investment Company K.S.C.P. (KWSE:KAMCO) and others.

An unknown buyer agreed to acquire 51% stake in Alpha Pharma L.L.C. from Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR).

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) agreed to acquire a 60% stake in Planet Pharmacies LLC.

First quarter 2021 earnings released: د.إ0.026 loss per share (vs د.إ0.094 loss in 1Q 2020)

Full year 2020 earnings released: د.إ0.28 loss per share (vs د.إ0.75 loss in FY 2019)

New 90-day low: د.إ1.26

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

New 90-day high: د.إ1.55

Radiant Pharmaceuticals Limited acquired Julphar Bangladesh Ltd from Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) and RAK Pharmaceuticals Pvt. Ltd. for BDT 1.4 billion.

Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

New 90-day high: د.إ1.50

Third quarter 2020 earnings released: د.إ0.015 loss per share

New 90-day high: د.إ1.49

New 90-day high: د.إ1.35

Earnings released

Gulf Pharmaceutical Industries P.S.C. has completed a Follow-on Equity Offering in the amount of AED 500 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken